Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents

Behavioral Neuropharmacology and NeuroImaging Lab, Medical Department, Building 490, Brookhaven National Laboratory, Upton, NY 11973-5000, United States.
Pharmacology Biochemistry and Behavior (Impact Factor: 2.78). 11/2007; 87(4):426-33. DOI: 10.1016/j.pbb.2007.05.020
Source: PubMed


Methylphenidate (MP) and amphetamine, which are the mainstay for the treatment of ADHD, have raised concerns because of their reinforcing effects and the fear that their chronic use during childhood or adolescence could induce changes in the brain that could facilitate drug abuse in adulthood.
Here we measured the effects of chronic treatment (8 months) with oral MP (1 or 2 mg/kg), which was initiated in periadolescent rats (postnatal day 30). Following this treatment, rats were tested on cocaine self-administration. In addition at 2 and 8 months of treatment we measured dopamine D2 receptor (D2R) availability in the striatum using [(11)C]raclopride microPET (microPET) imaging.
Animals treated for 8 months with 2 mg/kg of MP showed significantly reduced rates of cocaine self-administration at adulthood than vehicle treated rats. D2R availability in the striatum was significantly lower in rats after 2 months of treatment with MP (1 and 2 mg/kg) but significantly higher after 8 months of MP treatment than in the vehicle treated rats. In vehicle treated rats D2R availability decreased with age whereas it increased in rats treated with MP. Because low D2R levels in the striatum are associated with a propensity for self-administration of drugs both in laboratory animals and in humans, this effect could underlie the lower rates of cocaine self-administration observed in the rats given 8 months of treatment with MP.
Eight month treatment with oral MP beginning in adolescence decreased cocaine-self administration (1 mg/kg) during adulthood which could reflect the increases in D2R availability observed at this life stage since D2R increases are associated with reduced propensity for cocaine self administration. In contrast, two month treatment with MP started also at adolescence decreased D2R availability, which could raise concern that at this life stage short treatments could possibly increase vulnerability to drug abuse during adulthood. These findings indicate that MP effects on D2R expression in the striatum are sensitive not only to length of treatment but also to the developmental stage at which treatment is given. Future studies evaluating the effects of different lengths of treatment on drug self-administration are required to assess optimal duration of treatment regimes to minimize adverse effects on the propensity for drug self administration.

Download full-text


Available from: Panayotis Thanos,
  • Source
    • "Clinical evidence points to sensitive phases in development (e.g., early childhood) when pharmacological treatment for ADHD is most efficient (Zito et al., 2000). Several studies have proposed that both the timing of treatment onset and treatment duration influence the therapeutic effects of the drugs (Andersen et al., 2002; Thanos et al., 2007; Britton, 2011). In our study, the timing of treatment may be too late to modify the cognitive deficits of adult subjects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We established mouse models of extremes in trait anxiety, which are based on selective breeding for low vs. normal vs. high open-arm exploration on the elevated plus-maze. Genetically selected low anxiety-related behavior (LAB) coincided with hyperactivity in the home cage. Given the fact that several psychiatric disorders such as schizophrenia, mania, and attention deficit hyperactivity disorder (ADHD) share hyperactivity symptom, we systematically examined LAB mice with respect to unique and overlapping endophenotypes of the three diseases. To this end Venn diagrams were used as an instrument for discrimination of possible models. We arranged the endophenotypes in Venn diagrams and translated them into different behavioral tests. LAB mice showed elevated levels of locomotion in the open field (OF) test with deficits in habituation, compared to mice bred for normal (NAB) and high anxiety-related behavior (HAB). Cross-breeding of hypoactive HAB and hyperactive LAB mice resulted in offspring showing a low level of locomotion comparable to HAB mice, indicating that the HAB alleles are dominant over LAB alleles in determining the level of locomotion. In a holeboard test, LAB mice spent less time in hole exploration, as shown in patients with schizophrenia and ADHD; however, LAB mice displayed no impairments in social interaction and prepulse inhibition (PPI), implying a unlikelihood of LAB as an animal model of schizophrenia. Although LAB mice displayed hyperarousal, active coping styles, and cognitive deficits, symptoms shared by mania and ADHD, they failed to reveal the classic manic endophenotypes, such as increased hedonia and object interaction. The neuroleptic haloperidol reduced locomotor activity in all mouse lines. The mood stabilizer lithium and the psychostimulant amphetamine, in contrast, selectively reduced hyperactivity in LAB mice. Based on the behavioral and pharmacological profiles, LAB mice are suggested as a novel rodent model of ADHD-like symptoms.
    Frontiers in Behavioral Neuroscience 08/2013; 7:103. DOI:10.3389/fnbeh.2013.00103 · 3.27 Impact Factor
  • Source
    • "The present data draw a distinction from work by Thanos and colleagues who showed that chronic, oral MPH treatment was associated with a decrease in D2-like receptor availability after 2 months, and an increase in availability after 8 months of exposure (Thanos et al., 2007). MPH treatment has also been shown to have a lasting effect on presynaptic striatal dopamine function (Sproson et al., 2001), and to increase dendritic spine density on both D1-and D2-expressing medium spiny neurons in the shell of the nucleus accumbens (Kim et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rearing young rodents in socially isolated or environmentally enriched conditions has been shown to affect numerous components of the dopamine system as well as behavior. Methylphenidate (MPH), a commonly used dopaminergic agent, may affect animals differently based on rearing environment. Here we examined the interaction between environment and chronic MPH treatment at clinically relevant doses, administered via osmotic minipump. Young Sprague Dawley rats (PND 21) were assigned to environmentally enriched, pair-housed, or socially isolated rearing conditions, and treated with either 0, 2, 4, or 8mg/kg/day MPH for three weeks. At the end of the treatment period, animals were tested for locomotor activity and anxiety-like behavior. The densities of D1-like and D2-like receptors were measured in the striatum using in vitro receptor autoradiography. Locomotor activity and anxiety-like behavior were increased in isolated animals compared to pair-housed and enriched animals. The density of D1-like receptors was greater in isolated animals, but there were no differences between groups in D2-like receptor density. Finally, there were no effects of MPH administration on any reported measure. This study provides evidence for an effect of early rearing environment on the dopamine system and behavior, and also suggests that MPH administration may not have long-term consequences.
    Brain research 06/2013; 1527. DOI:10.1016/j.brainres.2013.06.021 · 2.84 Impact Factor
  • Source
    • "PET studies have uncovered significant reductions in D2R availability in the striatum of addicted subjects that persist for months after protracted detoxification [reviewed in (Volkow et al., 2009a)]. Similarly, preclinical studies in rodent and non-human primates have shown that repeated drug exposure is associated with reductions in striatal D2R levels (Nader et al., 2006; Thanos et al., 2007; Volkow et al., 2001). In the striatum, D2Rs mediate signaling in the striatal indirect pathway that modulates PFC regions ; and its downregulation has been shown to enhance sensitization to the effects of drugs in animal models (Ferguson et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Until very recently addiction-research was limited by existing tools and strategies that were inadequate for studying the inherent complexity at each of the different phenomenological levels. However, powerful new tools (e.g., optogenetics and designer drug receptors) and high throughput protocols are starting to give researchers the potential to systematically interrogate "all" genes, epigenetic marks, and neuronal circuits. These advances, combined with imaging technologies (both for preclinical and clinical studies) and a paradigm shift towards open access have spurred an unlimited growth of datasets transforming the way we investigate the neurobiology of substance use disorders (SUD) and the factors that modulate risk and resilience.
    Neuropharmacology 05/2013; 76. DOI:10.1016/j.neuropharm.2013.05.007 · 5.11 Impact Factor
Show more